REGN
Regeneron Pharmaceuticals Inc
961.30$
+3.6%
vs. previous close
Closing price · As of: Nov 2, 2026
Ownership
Ownership Structure
Who owns Regeneron Pharmaceuticals Inc (REGN)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 96.1% of the shares are freely tradable; institutional investors hold 92.3%.
Institutional ownership
?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
92.3%
Insiders
?Share of the stock held by the executives, founders and major shareholders of the company itself.
2.0%
Float
?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
96.1%
Short % of float
?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
2.2%
Shares Outstanding
?Total number of shares issued. Price times share count gives market cap.
102Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 8.81 | 9,113,506 | +1.9 | 06/30/2026 |
| Vanguard Capital Management, LLC | 6.41 | 6,629,759 | -0.4 | 06/30/2026 |
| Dodge & Cox | 4.71 | 4,871,137 | +9.3 | 06/30/2026 |
| State Street Corp | 4.67 | 4,834,688 | +3.6 | 06/30/2026 |
| Amvescap Plc. | 3.81 | 3,940,665 | +0.9 | 06/30/2026 |
| JPMorgan Chase & Co | 3.65 | 3,774,199 | -12.5 | 06/30/2026 |
| Vanguard Portfolio Management, LLC | 3.07 | 3,175,313 | +84.5 | 06/30/2026 |
| Franklin Templeton Inc | 2.68 | 2,771,839 | +1.8 | 06/30/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 3.10 | 3,211,682 | -1.9 | 09/30/2026 |
| Dodge & Cox Stock I | 2.99 | 3,089,092 | -1.1 | 09/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Murphy Andrew J | Co-Chief Scientific Officer | 47,833 | 45,981,863 $ | Oct 14, 2026 | direct |
| Larosa Joseph J | EVP General Counsel and Secret | 36,373 | 34,965,365 $ | Aug 19, 2026 | direct |
| Fenimore Christopher R. | EVP Finance CFO | 19,984 | 19,210,619 $ | Aug 18, 2026 | direct |
| McCourt Marion | EVP Commercial | 12,003 | 11,538,484 $ | Sep 3, 2026 | direct |
| Zoghbi Huda Y | Director | 1,703 | 1,637,094 $ | Aug 10, 2026 | direct |
| Guarini Kathryn | Director | 603 | 579,664 $ | Sep 2, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | Sell | 50 | 781.47 | 39,074 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | Sell | 463 | 780.63 | 361,432 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | Sell | 380 | 779.59 | 296,244 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | Sell | 454 | 778.64 | 353,503 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | Sell | 38 | 777.76 | 29,555 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | Sell | 66 | 776.31 | 51,236 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | Sell | 376 | 775.46 | 291,573 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | Sell | 121 | 774.48 | 93,712 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | Sell | 224 | 773.40 | 173,242 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | Sell | 211 | 772.56 | 163,010 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | Sell | 283 | 771.56 | 218,351 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | Sell | 12 | 770.20 | 9,242 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | Sell | 127 | 769.30 | 97,701 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | Sell | 105 | 768.33 | 80,675 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | Sell | 192 | 767.39 | 147,339 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | Sell | 279 | 766.47 | 213,845 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | Sell | 271 | 765.39 | 207,421 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | Sell | 219 | 764.40 | 167,404 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | Sell | 25 | 763.76 | 19,094 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | Sell | 55 | 762.57 | 41,941 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | Sell | 27 | 761.36 | 20,557 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | Sell | 74 | 760.65 | 56,288 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | Sell | 14 | 759.96 | 10,639 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | Sell | 24 | 758.16 | 18,196 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | Sell | 16 | 757.68 | 12,123 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | Sell | 35 | 755.91 | 26,457 |
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | Sell | 6 | 753.76 | 4,523 |
| Oct 13, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | Other | 12,853 | 754.58 | 9,698,617 |
| Oct 13, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | Other | 17,000 | 381.92 | 6,492,640 |
| Sep 3, 2026 | McCourt Marion | EVP Commercial | Sell | 1,131 | 857.39 | 969,708 |
| Sep 2, 2026 | Guarini Kathryn | Director | Sell | 400 | 850.00 | 340,000 |
| Sep 2, 2026 | Guarini Kathryn | Director | Other | 400 | 719.37 | 287,748 |
| Sep 2, 2026 | McCourt Marion | EVP Commercial | Sell | 1,215 | 850.00 | 1,032,750 |
| Aug 19, 2026 | Larosa Joseph J | EVP General Counsel and Secret | Other | 9,019 | 830.15 | 7,487,123 |
| Aug 19, 2026 | Larosa Joseph J | EVP General Counsel and Secret | Other | 12,282 | 381.92 | 4,690,741 |
| Aug 18, 2026 | Fenimore Christopher R. | EVP Finance CFO | Other | 4,599 | 813.47 | 3,741,149 |
| Aug 18, 2026 | Fenimore Christopher R. | EVP Finance CFO | Other | 6,283 | 381.92 | 2,399,603 |
| Aug 10, 2026 | Guarini Kathryn | Director | Sell | 400 | 800.00 | 320,000 |
| Aug 10, 2026 | Guarini Kathryn | Director | Other | 400 | 719.37 | 287,748 |
| Aug 10, 2026 | Zoghbi Huda Y | Director | Sell | 800 | 800.00 | 640,000 |
| Aug 10, 2026 | Zoghbi Huda Y | Director | Other | 800 | 376.69 | 301,352 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: November 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.